Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Administration
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Administration

1 evidence topic · 1 source

Investigational administration and treatment duration

“Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food” (opens the source at this quote in a new tab)
“52 weeks” (opens the source at this quote in a new tab)